Purpose/Objectives: To examine how neutropenia affects quality of life (QOL) and explore strategies to assess neutropenia-related QOL in clinical practice.
➤ Because the development of neutropenia and its associated reduction in quality of life (QOL) can affect treatment outcomes in patients with cancer receiving chemotherapy, healthcare professionals should assess such patients' QOL before the initiation of therapy and periodically throughout treatment. ➤ Several QOL measurement tools are available and widely used in research, but they may not be suitable for clinical practice. ➤ Customizing QOL measurement tools can make them more user friendly, practice specifi c, and clinically useful. ➤ Implementation of a QOL screening questionnaire for neutropenia could help nurses identify at-risk patients and guide interventions that could have a positive infl uence on patients' treatments.
Q
uality of life (QOL) is a multidimensional concept that assesses the extent to which a person's usual or expected physical, emotional, and social well-being is affected by a medical condition or its treatment (Cella, Chang, Lai, & Webster, 2002) . QOL, symptom status, and functional status frequently are considered to be interchangeable, but they represent three related but ultimately distinct concepts (Ropka, 2002) . Symptom status refers to a patient's experience of physical, emotional, or cognitive manifestations of illness or treatment, such as nausea, anxiety, or confusion. Functional status refers to the effect of illness or treatment on a patient's ability to perform day-to-day tasks involved in work, self-care, and maintenance of family or social roles. QOL, which encompasses symptom status and functional status, is a broad concept refl ecting an individual's overall satisfaction with life or sense of well-being (Ropka). QOL endpoints for cancer treatments increasingly are recognized as secondary in importance only to survival and disease progression. In the palliative setting, QOL outcomes are paramount (American Society of Clinical Oncology, 1996; Levine & Ganz, 2002; Sloan, Cella, Frost, Guyatt, & Osoba, 2003) . Clinical questionnaires to evaluate QOL are used widely in oncology nursing practice because of their value in guiding patient treatment and care (Dunckley, Hughes, Addington-Hall, & Higginson, 2003) . In this context, the term "instrument" generally refers to a questionnaire in which patients answer questions about symptoms, functioning, or feelings, often stating answers in a numerical or graded form (e.g., expressing the intensity of pain on a scale of 0 -10 or as mild, moderate, or severe).
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